Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Study Details
Study Description
Brief Summary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. The objective of the study is to determine whether this drug combination is safe for this patient population and to see if it is effective in shrinking cancers, keeping them from growing or helping patients live longer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Patients who consent to this study will receive treatment for four 28 day cycles unless they are unable to continue study treatment due to toxicity or disease progression. Paclitaxel and carboplatin will be given intravenously on day 1 of each cycle and galunisertib in pill form on days 4-17. No medicine will be given on days 17-28 of each cycle. Patients may have the option of continuing treatment with the study drug if they complete the 4 cycles the study requires. Subjects will receive tests and procedures that are part of regular cancer care as well as those required for the purposes of the study. Blood samples will be taken to monitor the level of study drug in the blood. Patients will have the option of allowing blood and tumor samples to be used for future research.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Paclitaxel/Carboplatin + Galunisertib
|
Drug: Galunisertib
Galunisertib 150mg po BID day 4-17.)
Drug: Paclitaxel
Paclitaxel 175 mg/m2 over 3 hours
Drug: Carboplatin
IV day 1 Carboplatin AUC 6* over 1 hour (or 5* if no prior radiation therapy)
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients with completion of 4 cycles of CT + GB [2 years]
To determine the feasibility of delivering 4 cycles of carboplatin/paclitaxel (CT) in combination with galunisertib (GB) to patients with gynecologic carcinosarcoma
Secondary Outcome Measures
- Incidence and severity of adverse events [2 years]
To determine the frequency and severity of adverse events as assessed by the CTCAE v4
- Median progression free survival (months) [through study completion, an average of 3 years]
To determine the PFS of patients receiving drug combination
- Mean (SD) of GB serum concentration levels on day 4, 8 and 29 (cycle 2 day 1) [2 months]
Galunisertib serum concentration levels will be tested
- Median overall survival (months) [through study completion, an average of 3 years]
To determine the overall survival of patients receiving drug combination
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women ≥ 18 years old with a diagnosis of primary, recurrent or progressive uterine, ovarian, fallopian tube or peritoneal carcinosarcoma, for whom treatment with combination paclitaxel and carboplatin is recommended.
-
Written informed consent/assent prior to any study-specific procedures
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Tissue available for translational study (paraffin block or new biopsy) .
-
Adequate bone marrow, renal, and hepatic function as defined per protocol.
-
No disease-modifying therapy, including investigational treatments, within 28 days prior to initiation of study treatment.
-
Ability to swallow tablets
-
For Women of child-bearing potential:Willingness to use a highly effective method of contraception during the study and for 6 months following the last dose of galunisertib. Negative beta human chorionic gonadotropin pregnancy test documented within 7 days prior to initiation of study drug.
-
Patient must have measurable disease before the treatment
Exclusion Criteria:
-
Planned radiotherapy during or after the study chemotherapy prior to disease progression.
-
Receipt of chemotherapy or radiation within 28 days of study treatment
-
Have had a major surgical procedure or a significant traumatic injury within 28 days prior to study treatment; Minor procedures such as biopsy within 7 days prior to study treatment are allowed.
-
Active infection that would preclude receipt of chemotherapy
-
Moderate or severe cardiovascular disease per protocol
-
Active pregnancy or lactation
-
Second primary malignancy for which treatment during the study period would be recommended if this cancer were not also present.
-
Prior malignancy requiring treatment within the last 3 years
-
Use of another investigational product or device within 4 weeks of study entry or during study participation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stephenson Cancer Center, University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
Sponsors and Collaborators
- University of Oklahoma
- Eli Lilly and Company
Investigators
- Principal Investigator: Kathleen Moore, MD, Obstetrics and Gynecology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OU-SCC-EXIST-001